Abstract: The present invention provides diagnostic and therapeutic methods and compositions for treating a patient suffering from an interleukin-1 receptor-associated kinase 4 (IRAK4)-mediated disorder or condition, such as an immune disorder (e.g., systemic lupus erythematosus (SLE)) or an inflammatory disorder (e.g., asthma). The invention provides diagnostic methods of monitoring the response of a patient having an IRAK4-mediated disorder or condition to treatment including an IRAK4 pathway inhibitor, methods of identifying a patient having an IRAK4-mediated disorder or condition who may benefit from treatment including an IRAK4 pathway inhibitor, and methods of selecting a therapy for a patient having an IRAK4-mediated disorder or condition based on the expression level of one or more IRAK4 biomarkers (e.g., one or more genes set forth in Table 1). Related therapeutic methods and compositions (e.g., diagnostic kits) are also provided.

Abstract: Described herein is a novel receptor-ligand interaction and agents that may modify and/or block the interaction. Methods, uses, reagents and kits for the modulation of ligand activities related to its interaction with the novel receptor are disclosed. Also disclosed are therapeutic uses of reagents in treating inflammation-related disorders.

Abstract: Described herein is a novel receptor-ligand interaction and agents that may modify and/or block the interaction. Methods, uses, reagents and kits for the modulation of ligand activities related to its interaction with the novel receptor are disclosed. Also disclosed are therapeutic uses of reagents in treating inflammation-related disorders.

Abstract: Described herein is a novel receptor-ligand interaction and agents that may modify and/or block the interaction. Methods, uses, reagents and kits for the modulation of ligand activities related to its interaction with the novel receptor are disclosed. Also disclosed are therapeutic uses of reagents in treating inflammation-related disorders.

Abstract: Described herein is a novel receptor-ligand interaction and agents that may modify and/or block the interaction. Methods, uses, reagents and kits for the modulation of ligand activities related to its interaction with the novel receptor are disclosed. Also disclosed are therapeutic uses of reagents in treating inflammation-related disorders.

Abstract: Described herein is a novel receptor-ligand interaction and agents that may modify and/or block the interaction. Methods, uses, reagents and kits for the modulation of ligand activities related to its interaction with the novel receptor are disclosed. Also disclosed are therapeutic uses of reagents in treating inflammation-related disorders.

Abstract: Described herein is a novel receptor-ligand interaction and agents that may modify and/or block the interaction. Methods, uses, reagents and kits for the modulation of ligand activities related to its interaction with the novel receptor are disclosed. Also disclosed are therapeutic uses of reagents in treating inflammation-related disorders.

Abstract: Described herein are recombinant non-human cells and animals having an alteration of the S? region such that there is an elevated IgE level. Also described herein is an alteration in the IgH locus allows for enhanced class switch recombination (CSR) such that the desired heavy chain isotype is expressed at an elevated level relative to an unmodified cell.